StreetInsider.com News Articles

Healthcare Stocks Rushing Higher, with Oncology Push, Breakout Test, and Lilly’s Next Growth Chapter

Thu, 22 Oct 2026 14:27:09 -0400

DENVER, Oct. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Healthcare stocks are presenting investors with a mix of pharmaceutical growth stories and catalysts. Pfizer (NYSE: PFE) is drawing renewed attention to its oncology pipeline, while NeOnc Technologies Holdings (NASDAQ: NTHI) is combining brain-cancer research developments with a closely watched technical rebound. Avantor (NYSE: AVTR) is approaching another earnings test as a supplier to the life-sciences industry, and Eli Lilly and Co (NYSE: LLY) continues to build on its strong drug portfolio with encouraging pediatric clinical data.

Oncology Progress Reignites Interest as Pfizer Looks Beyond

Healthcare Stocks Rushing Higher, with Oncology Push, Breakout Test, and Lilly’s Next Growth Chapter

Thu, 22 Oct 2026 14:27:09 -0400

DENVER, Oct. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Healthcare stocks are presenting investors with a mix of pharmaceutical growth stories and catalysts. Pfizer (NYSE: PFE) is drawing renewed attention to its oncology pipeline, while NeOnc Technologies Holdings (NASDAQ: NTHI) is combining brain-cancer research developments with a closely watched technical rebound. Avantor (NYSE: AVTR) is approaching another earnings test as a supplier to the life-sciences industry, and Eli Lilly and Co (NYSE: LLY) continues to build on its strong drug portfolio with encouraging pediatric clinical data.

Oncology Progress Reignites Interest as Pfizer Looks Beyond

Healthcare Stocks Rushing Higher, with Oncology Push, Breakout Test, and Lilly’s Next Growth Chapter

Thu, 22 Oct 2026 14:27:09 -0400

DENVER, Oct. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Healthcare stocks are presenting investors with a mix of pharmaceutical growth stories and catalysts. Pfizer (NYSE: PFE) is drawing renewed attention to its oncology pipeline, while NeOnc Technologies Holdings (NASDAQ: NTHI) is combining brain-cancer research developments with a closely watched technical rebound. Avantor (NYSE: AVTR) is approaching another earnings test as a supplier to the life-sciences industry, and Eli Lilly and Co (NYSE: LLY) continues to build on its strong drug portfolio with encouraging pediatric clinical data.

Oncology Progress Reignites Interest as Pfizer Looks Beyond

Healthcare Stocks Rushing Higher, with Oncology Push, Breakout Test, and Lilly’s Next Growth Chapter

Thu, 22 Oct 2026 14:27:09 -0400

DENVER, Oct. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Healthcare stocks are presenting investors with a mix of pharmaceutical growth stories and catalysts. Pfizer (NYSE: PFE) is drawing renewed attention to its oncology pipeline, while NeOnc Technologies Holdings (NASDAQ: NTHI) is combining brain-cancer research developments with a closely watched technical rebound. Avantor (NYSE: AVTR) is approaching another earnings test as a supplier to the life-sciences industry, and Eli Lilly and Co (NYSE: LLY) continues to build on its strong drug portfolio with encouraging pediatric clinical data.

Oncology Progress Reignites Interest as Pfizer Looks Beyond

Healthcare Stocks Rushing Higher, with Oncology Push, Breakout Test, and Lilly’s Next Growth Chapter

Thu, 22 Oct 2026 14:27:09 -0400

DENVER, Oct. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Healthcare stocks are presenting investors with a mix of pharmaceutical growth stories and catalysts. Pfizer (NYSE: PFE) is drawing renewed attention to its oncology pipeline, while NeOnc Technologies Holdings (NASDAQ: NTHI) is combining brain-cancer research developments with a closely watched technical rebound. Avantor (NYSE: AVTR) is approaching another earnings test as a supplier to the life-sciences industry, and Eli Lilly and Co (NYSE: LLY) continues to build on its strong drug portfolio with encouraging pediatric clinical data.

Oncology Progress Reignites Interest as Pfizer Looks Beyond

Healthcare Stocks Rushing Higher, with Oncology Push, Breakout Test, and Lilly’s Next Growth Chapter

Thu, 22 Oct 2026 14:27:09 -0400

DENVER, Oct. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Healthcare stocks are presenting investors with a mix of pharmaceutical growth stories and catalysts. Pfizer (NYSE: PFE) is drawing renewed attention to its oncology pipeline, while NeOnc Technologies Holdings (NASDAQ: NTHI) is combining brain-cancer research developments with a closely watched technical rebound. Avantor (NYSE: AVTR) is approaching another earnings test as a supplier to the life-sciences industry, and Eli Lilly and Co (NYSE: LLY) continues to build on its strong drug portfolio with encouraging pediatric clinical data.

Oncology Progress Reignites Interest as Pfizer Looks Beyond

Healthcare Stocks Rushing Higher, with Oncology Push, Breakout Test, and Lilly’s Next Growth Chapter

Thu, 22 Oct 2026 14:27:09 -0400

DENVER, Oct. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Healthcare stocks are presenting investors with a mix of pharmaceutical growth stories and catalysts. Pfizer (NYSE: PFE) is drawing renewed attention to its oncology pipeline, while NeOnc Technologies Holdings (NASDAQ: NTHI) is combining brain-cancer research developments with a closely watched technical rebound. Avantor (NYSE: AVTR) is approaching another earnings test as a supplier to the life-sciences industry, and Eli Lilly and Co (NYSE: LLY) continues to build on its strong drug portfolio with encouraging pediatric clinical data.

Oncology Progress Reignites Interest as Pfizer Looks Beyond

Healthcare Stocks Rushing Higher, with Oncology Push, Breakout Test, and Lilly’s Next Growth Chapter

Thu, 22 Oct 2026 14:27:09 -0400

DENVER, Oct. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Healthcare stocks are presenting investors with a mix of pharmaceutical growth stories and catalysts. Pfizer (NYSE: PFE) is drawing renewed attention to its oncology pipeline, while NeOnc Technologies Holdings (NASDAQ: NTHI) is combining brain-cancer research developments with a closely watched technical rebound. Avantor (NYSE: AVTR) is approaching another earnings test as a supplier to the life-sciences industry, and Eli Lilly and Co (NYSE: LLY) continues to build on its strong drug portfolio with encouraging pediatric clinical data.

Oncology Progress Reignites Interest as Pfizer Looks Beyond

Increasing unusual option volume: BMBL FUN MUB AVTR CCC ITUB SPAX INSM AMRZ

Tue, 13 Oct 2026 10:51:31 -0400

Increasing unusual option volume: BMBL FUN MUB AVTR CCC ITUB SPAX INSM AMRZ

Increasing unusual option volume: BMBL FUN MUB AVTR CCC ITUB SPAX INSM AMRZ

Tue, 13 Oct 2026 10:51:31 -0400

Increasing unusual option volume: BMBL FUN MUB AVTR CCC ITUB SPAX INSM AMRZ

Avantor Inc. (AVTR) PT Raised to $17 at TD Cowen

Tue, 13 Oct 2026 09:30:36 -0400
TD Cowen analyst Dan Brennan raised the price target on Avantor Inc. (NYSE: AVTR) to $17.00 (from $15.00) while maintaining a rating.

Avantor Inc. (AVTR) PT Raised to $15 at Morgan Stanley

Tue, 13 Oct 2026 08:23:14 -0400
Morgan Stanley analyst Tejas Savant raised the price target on Avantor Inc. (NYSE: AVTR) to $15.00 (from $14.00) while maintaining a Equalweight rating.

Avantor (AVTR) 4K contracts of January 16 calls trade

Fri, 09 Oct 2026 05:05:43 -0400

Avantor (NYSE: AVTR) 30-day option implied volatility is at 24; compared to its 52-week range of 32 to 88 with a focus on 4K contracts of January 16 calls.

Avantor Inc. (AVTR) PT Raised to $17 at Baird

Thu, 08 Oct 2026 07:22:54 -0400
Baird analyst Catherine Schulte raised the price target on Avantor Inc. (NYSE: AVTR) to $17.00 (from $16.00) while maintaining a Outperform rating.

Avantor Inc. (AVTR) PT Raised to $15 at Barclays

Wed, 07 Oct 2026 03:48:40 -0400
Barclays analyst Luke Sergott raised the price target on Avantor Inc. (NYSE: AVTR) to $15.00 (from $13.00) while maintaining a Underweight rating.

KeyBanc's Preview of 'Biggest Potential Beats in Life Science'

Mon, 05 Oct 2026 08:40:35 -0400

KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.
The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1

KeyBanc's Preview of 'Biggest Potential Beats in Life Science'

Mon, 05 Oct 2026 08:40:35 -0400

KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.
The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1

KeyBanc's Preview of 'Biggest Potential Beats in Life Science'

Mon, 05 Oct 2026 08:40:35 -0400

KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.
The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1

KeyBanc's Preview of 'Biggest Potential Beats in Life Science'

Mon, 05 Oct 2026 08:40:35 -0400

KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.
The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1

KeyBanc's Preview of 'Biggest Potential Beats in Life Science'

Mon, 05 Oct 2026 08:40:35 -0400

KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.
The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1

KeyBanc's Preview of 'Biggest Potential Beats in Life Science'

Mon, 05 Oct 2026 08:40:35 -0400

KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.
The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1

KeyBanc's Preview of 'Biggest Potential Beats in Life Science'

Mon, 05 Oct 2026 08:40:35 -0400

KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.
The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1

KeyBanc's Preview of 'Biggest Potential Beats in Life Science'

Mon, 05 Oct 2026 08:40:35 -0400

KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.
The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1

KeyBanc's Preview of 'Biggest Potential Beats in Life Science'

Mon, 05 Oct 2026 08:40:35 -0400

KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.
The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1

KeyBanc's Preview of 'Biggest Potential Beats in Life Science'

Mon, 05 Oct 2026 08:40:35 -0400

KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.
The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1